Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238116 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
A Phase 3 study, sponsored by Pulmocide.
- Terminated
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
NCT05238116 is a Phase 3 study that was terminated before completion, run by Pulmocide. The registered enrollment target is 85 participants.
The verdict
NCT05238116, a Phase 3 study, was terminated before completion, sponsored by Pulmocide.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Interventions
- DRUG Placebo
- DRUG PC945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-06-14 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238116
The ClinicalTrials.gov registry entry for NCT05238116 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulmocide, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05238116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238116 about?
NCT05238116 is a clinical study titled "Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)". To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
What is the current status of trial NCT05238116?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 2022-06-14. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT05238116?
The interventions under investigation include: Placebo (DRUG), PC945 (DRUG).
Who is sponsoring clinical trial NCT05238116?
This trial is sponsored by Pulmocide, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.